# DESCRIPTION

- relate invention to treatment

## TECHNICAL BACKGROUND

### Chronic Fatigue Syndrome

- define chronic fatigue syndrome
- describe symptoms
- discuss prevalence
- discuss aetiology
- motivate research priorities
- summarize gene expression studies
- discuss immune system deregulation
- discuss viral infections
- discuss cytokine production
- discuss immune cell function
- discuss laboratory markers
- discuss T- and NK-cell subsets
- discuss B-cell subsets
- discuss perforin expression
- discuss CD69 expression
- discuss autoimmunity hypotheses
- discuss antinuclear autoantibodies
- discuss muscarinic cholinergic receptor autoantibodies
- discuss insoluble cellular antigens
- conclude no direct evidence for autoimmune disease

### Current Treatment of CFS

- discuss lack of standard treatment
- motivate biopsychosocial model
- discuss intravenous gammaglobulin therapy
- discuss etanercept therapy
- discuss other therapeutic strategies

### Rituximab as an Example of B-Cell Depleting Antibodies in B-Cell Lymphoma and Autoimmunity

- introduce Rituximab
- describe structure of Rituximab
- explain mechanism of action of Rituximab
- discuss role of Rituximab in treatment of B-cell lymphomas
- summarize efficacy of Rituximab in clinical trials
- mention use of Rituximab in autoimmune diseases
- list patents and patent publications concerning CD20 antibodies
- describe in vitro mechanism of action of Rituximab
- discuss synergy between Rituximab and chemotherapies
- summarize in vivo preclinical studies of Rituximab
- mention development of antibodies to specific B-cell subsets
- discuss future B-cell targeting and depletion
- mention next generation of anti CD-20 antibodies

### Safety Profile of Rituximab

- discuss safety profile of Rituximab in treatment of B-cell lymphomas
- describe side-effects of Rituximab
- mention concern with humoral immunity
- discuss potential serious side-effect of interstitial lung disease
- mention long-term safety of Rituximab in autoimmune diseases

## BRIEF DESCRIPTION OF THE PRESENT INVENTION

- introduce chronic fatigue syndrome treatment
- describe B-cell depleting agents

## DETAILED DESCRIPTION OF THE INVENTION

- introduce chronic fatigue syndrome/myalgic encephalomyelitis
- define B-cell depletion
- describe CD20 antigen
- define B-cell
- introduce antagonists of CD20 molecule
- describe antibody-dependent cell-mediated cytotoxicity (ADCC)
- describe complement dependent cytotoxicity (CDC)
- describe apoptosis
- define antibody
- describe Fv fragment
- describe Fab fragment
- describe Fab′ fragment
- describe F(ab′)2 fragment
- describe diabodies
- define monoclonal antibody
- describe production of monoclonal antibodies
- describe chimeric antibodies
- describe humanized antibodies
- describe primatized antibodies
- describe naked antibody
- introduce examples of antibodies that bind CD20
- describe Rituximab
- describe Ibritumomab Tiuxetan
- describe Tositumomab
- describe 1F5 antibody
- describe 2H7 antibody
- describe Ofatumumab
- describe AME-133
- describe A20 antibody
- describe Ocrelizumab
- describe GA101
- describe BLX-301
- describe Veltuzumab
- describe DXL625
- introduce other B-cell depleting agents
- describe Epratuzumab
- describe MDX-1342
- define effective amount of B-cell depleting agent
- describe dosage of Rituximab
- describe dosage of Methotrexate
- introduce small modular immunopharmaceuticals (SMIP)
- describe TRU-015
- describe SBI-087
- describe combination therapy
- describe administration of B-cell depleting agent
- describe methods for generating B-cell depleting antagonists

### (i) Polyclonal Antibodies

- raise polyclonal antibodies in animals
- conjugate antigen to immunogenic protein
- immunize and boost animals

### (ii) Monoclonal Antibodies

- define monoclonal antibodies
- describe hybridoma method
- describe recombinant DNA methods
- isolate DNA encoding monoclonal antibodies
- place DNA into expression vectors
- transfect host cells
- obtain synthesis of monoclonal antibodies
- review recombinant expression in bacteria
- isolate antibodies from antibody phage libraries
- describe production of high affinity human antibodies
- modify DNA by substituting human heavy- and light chain constant domains
- create chimeric bivalent antibody

### (iv) Human Antibodies

- generate human antibodies
- produce transgenic animals
- transfer human germ-line immunoglobulin gene array
- use phage display technology
- generate human antibodies from unimmunized donors

### (v) Antibody Fragments

- produce antibody fragments by proteolytic digestion
- produce antibody fragments by recombinant host cells

### Pharmaceutical Formulations

- prepare therapeutic formulations
- mix antibody with pharmaceutically acceptable carriers
- describe acceptable carriers and excipients
- describe preservatives and antioxidants
- describe hydrophilic polymers and amino acids
- describe chelating agents and sugars
- describe salt-forming counter-ions and metal complexes
- describe non-ionic surfactants

## EXAMPLES

- introduce patient with CFS
- observe symptom improvement after chemotherapy
- motivate B-cell depletion as treatment for CFS
- describe pilot patient 1 treatment and results
- introduce Rituximab as B-cell depletion agent

### Pilot Patient 1:

- describe patient's condition before treatment
- administer Rituximab treatment
- report symptom improvement after treatment
- describe repeated treatment and results

### Pilot Patient 2:

- describe patient's condition before treatment
- administer Rituximab treatment
- report symptom improvement after treatment

### Pilot Patient 3:

- describe patient's condition before treatment
- administer Rituximab treatment
- report initial symptom improvement
- describe delayed major clinical response
- report relapse and repeated treatment
- describe Methotrexate treatment and results

